Entera Bio (NASDAQ:ENTX) Issues Quarterly Earnings Results

Entera Bio (NASDAQ:ENTXGet Rating) posted its quarterly earnings results on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.05, Fidelity Earnings reports. Entera Bio had a negative net margin of 2,134.33% and a negative return on equity of 59.83%. During the same period last year, the company earned ($0.43) EPS.

Shares of NASDAQ ENTX traded up $0.06 during midday trading on Friday, hitting $2.15. The company’s stock had a trading volume of 68,010 shares, compared to its average volume of 81,024. The stock has a fifty day moving average price of $2.50 and a 200 day moving average price of $2.80. Entera Bio has a one year low of $1.72 and a one year high of $8.68. The firm has a market capitalization of $50.96 million, a price-to-earnings ratio of -4.67 and a beta of 1.64.

Separately, B. Riley lowered their price target on shares of Entera Bio from $11.00 to $6.00 in a research report on Monday, January 24th.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its stake in Entera Bio by 145.6% during the third quarter. Morgan Stanley now owns 5,378 shares of the company’s stock valued at $25,000 after acquiring an additional 3,188 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in Entera Bio during the first quarter valued at approximately $29,000. Jane Street Group LLC purchased a new position in Entera Bio during the third quarter valued at approximately $54,000. Finally, Renaissance Technologies LLC purchased a new position in Entera Bio during the fourth quarter valued at approximately $113,000. 23.87% of the stock is currently owned by institutional investors.

Entera Bio Company Profile (Get Rating)

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

Recommended Stories

Earnings History for Entera Bio (NASDAQ:ENTX)

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.